Assembly Biosciences, Inc. (ASMB)
34.07
-0.73
(-2.10%)
USD |
NASDAQ |
Aug 28, 16:00
34.00
-0.07
(-0.21%)
After-Hours: 20:00
Assembly Biosciences Gross Profit Margin (Quarterly) : 99.85% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 99.85% |
| March 31, 2026 | 99.68% |
| December 31, 2025 | 99.92% |
| September 30, 2025 | 99.70% |
| June 30, 2025 | 99.67% |
| March 31, 2025 | 99.65% |
| December 31, 2024 | 99.56% |
| September 30, 2024 | 99.52% |
| June 30, 2024 | 99.62% |
| March 31, 2024 | 99.45% |
| December 31, 2023 | 98.83% |
| September 30, 2023 | |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 |
| Date | Value |
|---|---|
| September 30, 2021 | 0.00% |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | 0.00% |
| September 30, 2020 | 0.00% |
| June 30, 2020 | 0.00% |
| March 31, 2020 | 0.00% |
| December 31, 2019 | 0.00% |
| September 30, 2019 | 0.00% |
| June 30, 2019 | 0.00% |
| March 31, 2019 | 0.00% |
| December 31, 2018 | 0.00% |
| September 30, 2018 | 0.00% |
| June 30, 2018 | 0.00% |
| March 31, 2018 | 0.00% |
| December 31, 2017 | 0.00% |
| September 30, 2017 | 0.00% |
| June 30, 2017 | 0.00% |
| March 31, 2017 | 95.34% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Gilead Sciences, Inc. | 79.81% |
| BridgeBio Pharma, Inc. | 93.68% |
| ACADIA Pharmaceuticals, Inc. | 90.81% |
| Alnylam Pharmaceuticals, Inc. | 76.88% |
| Anika Therapeutics, Inc. | 65.15% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -0.02% |
| Return on Assets | -0.02% |
| Return on Invested Capital | -0.02% |
| Profit Margin (Quarterly) | -28.84% |
| Operating Margin (Quarterly) | -47.44% |
| Return on Net Operating Assets | -1.24% |